FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports
The U.S. Food and Drug Administration will reverse its earlier rejection of a rare-disease therapy from Regenxbio, the Wall Street Journal reported on Monday.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Diti Pujara)
Copyright Reuters or USA Today Network via Reuters Connect
This story was originally published June 22, 2026 at 6:09 AM.